Published May 25, 2021
Medical Xpress and Science Magazine reported on research led by biomedical engineer Jonathan Lovell that found an experimental nanoparticle-based flu vaccine consisting of disease-fighting proteins was proven effective in preclinical studies.
The technology could boost the effectiveness and accelerate the production of seasonal flu vaccines.
"Typically, flu vaccines contain either deactivated microbes that cause influenza, or they are based on weakened forms of the disease. The vaccine we're developing is a recombinant protein nanoparticle vaccine that stimulates a strong immune response," says Lovell, an associate professor and SUNY Empire Innovation professor in the Department of Biomedical Engineering.
The paper, "A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge," was published in the Proceedings of the National Academy of Sciences.
Read the stories here: Medical Xpress and Science Magazine.
